Naspm trihydrochloride

Pricing Availability   Qty
Description: Ca2+-permeable AMPA antagonist
Alternative Names: 1-Naphthyl acetyl spermine trihydrochloride
Chemical Name: N-[3-[[4-[(3-Aminopropyl)amino]butyl]amino]propyl]-1-naphthaleneacetamide trihydrochloride
Purity: ≥97% (HPLC)
Datasheet
Citations (13)
Reviews (1)
Literature (4)

Biological Activity for Naspm trihydrochloride

Naspm trihydrochloride is a selective antagonist of Ca2+-permeable AMPA receptors; blocks AMPA receptors lacking the GluA2 subunit. Protects hippocampal neurons against global ischemia-induced cell death.

Technical Data for Naspm trihydrochloride

M. Wt 479.91
Formula C22H34N4O.3HCl
Storage Desiccate at +4°C
Purity ≥97% (HPLC)
CAS Number 1049731-36-3
PubChem ID 16219727
InChI Key JNEOJAUJWOPWJS-UHFFFAOYSA-N
Smiles O=C(NCCCNCCCCNCCCN)CC2=CC=CC1=CC=CC=C12.Cl.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Naspm trihydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 47.99 100

Preparing Stock Solutions for Naspm trihydrochloride

The following data is based on the product molecular weight 479.91. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.08 mL 10.42 mL 20.84 mL
5 mM 0.42 mL 2.08 mL 4.17 mL
10 mM 0.21 mL 1.04 mL 2.08 mL
50 mM 0.04 mL 0.21 mL 0.42 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Naspm trihydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Naspm trihydrochloride

References are publications that support the biological activity of the product.

Tsubokawa et al (1995) Effects of spider toxin and its analogue on glutamate-activated currents in the hippocampal CA1 neuron after ischaemia. J.Neurophysiol. 74 218 PMID: 7472325

Koike et al (1997) Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci.Res. 29 27 PMID: 9293490

Nilsen and England (2007) A subtype-selective, use-dependent inhibitor of native AMPA receptors. J.Am.Chem.Soc. 129 4902 PMID: 17391037

Noh et al (2005) Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc.Natl.Acad.Sci.USA 102 12230


If you know of a relevant reference for Naspm trihydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Antagonists

Keywords: Naspm trihydrochloride, Naspm trihydrochloride supplier, AMPA, receptors, antagonists, GluR2, calcium-permeable, Ca2+, ionotropic, glutamate, iGluR, GluA2, 1-Naphthyl, acetyl, spermine, trihydrochloride, Receptors, 2766, Tocris Bioscience

13 Citations for Naspm trihydrochloride

Citations are publications that use Tocris products. Selected citations for Naspm trihydrochloride include:

Liu et al (2013) Long-term potentiation of synaptic transmission in the adult mouse insular cortex: multielectrode array recordings. J Neurophysiol 110 505 PMID: 23636718

Cabañero et al (2013) Pain after discontinuation of mor. treatment is associated with synaptic increase of GluA4-containing AMPAR in the dorsal horn of the spinal cord. Neuropsychopharmacology 38 1472 PMID: 23403695

Zhang et al (2019) Müller Glial Cells Participate in Retinal Waves via Glutamate Transporters and AMPA Receptors. Cell Rep 27 2871 PMID: 31167134

Jaafari et al (2012) PICK1 mediates transient synaptic expression of GluA2-lacking AMPA receptors during glycine-induced AMPA receptor trafficking. J Neurosci 32 11618 PMID: 22915106

Villers et al (2012) Long-lasting LTP requires neither repeated trains for its induction nor protein synthesis for its development. PLoS One 7 e40823 PMID: 22792408

Park et al (2016) Calcium-Permeable AMPA Receptors Mediate the Induction of the Protein Kinase A-Dependent Component of Long-Term Potentiation in the Hippocampus. J Neurosci 36 622 PMID: 26758849

Megill et al (2015) Defective Age-Dependent Metaplasticity in a Mouse Model of Alzheimer's Disease. Nature 35 11346 PMID: 26269641

Kim and Ziff (2014) Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors. PLoS Biol 12 e1001900 PMID: 24983627

Fernandes et al (2014) In vitro ischemia triggers a transcriptional response to down-regulate synaptic proteins in hippocampal neurons. PLoS One 9 e99958 PMID: 24960035

Purkey et al (2018) AKAP150 Palmitoylation Regulates Synaptic Incorporation of Ca2+-Permeable AMPA Receptors to Control LTP. Cell Rep 25 974 PMID: 30355502

Roy et al (2014) Enhancement of morphological plasticity in hippocampal neurons by a physically modified saline via phosphatidylinositol-3 kinase. J Neurosci 9 e101883 PMID: 25007337

Lee et al (2014) Synapse elimination and learning rules co-regulated by MHC class I H2-Db. J Cereb Blood Flow Metab 509 195 PMID: 24695230

Blanco-Suárez et al (2014) Differential Tiam1/Rac1 activation in hippocampal and cortical neurons mediates differential spine shrinkage in response to oxygen/glucose deprivation. Nat Commun 34 1898 PMID: 25248834


Do you know of a great paper that uses Naspm trihydrochloride from Tocris? Please let us know.

Reviews for Naspm trihydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Naspm trihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


calcium permeable AMPA receptor blocker.
By Karthik krishnamurthy on 11/02/2018
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: spinal cord neurons

used to block calcium permeable AMPA receptors in spinal cord neurons at a concentration of 25 micromolar

Reference
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.